Scientech Research LLC Neurocrine Biosciences Inc Transaction History
Scientech Research LLC
- $485 Billion
- Q2 2024
A detailed history of Scientech Research LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Scientech Research LLC holds 1,516 shares of NBIX stock, worth $184,239. This represents 0.04% of its overall portfolio holdings.
Number of Shares
1,516
Previous 4,474
66.12%
Holding current value
$184,239
Previous $617 Million
66.18%
% of portfolio
0.04%
Previous 0.33%
Shares
2 transactions
Others Institutions Holding NBIX
# of Institutions
623Shares Held
95.5MCall Options Held
661KPut Options Held
221K-
Black Rock Inc. New York, NY14.2MShares$1.72 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.22 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$560 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$300 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$287 Million0.03% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.6B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...